Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: Risks versus benefits

Expert Review of Clinical Pharmacology

Volumn 8, Issue 2, 2015, Pages 221-231

  Pucci, Mark ^a   Sarween, Nadia ^a   Knox, Ellen ^b   Lipkin, Graham ^a   Martin, Una ^c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; chronic kidney disease; congenital malformations; first trimester; hypertension; pregnancy; teratogenicity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT;

CHRONIC KIDNEY DISEASE; CONGENITAL MALFORMATION; DRUG EXPOSURE; FIRST TRIMESTER PREGNANCY; HUMAN; KIDNEY FUNCTION; MATERNAL HYPERTENSION; NONHUMAN; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; REVIEW; RISK BENEFIT ANALYSIS; TERATOGENESIS; URINARY EXCRETION; ABNORMALITIES, DRUG-INDUCED; ANIMAL; COMPLICATION; CONGENITAL ABNORMALITIES; DRUG EFFECTS; FEMALE; FETUS; HYPERTENSION; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

ABNORMALITIES, DRUG-INDUCED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CONGENITAL ABNORMALITIES; FEMALE; FETUS; HUMANS; HYPERTENSION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY TRIMESTERS;

EID: 84923385628     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.1005074     Document Type: Review

References (63)

1. Health and Social Care Information Centre. Prescriptions dispensed in the community: England 2002-12. Available from: www. hscic.gov.uk/catalogue/PUB11291/pres-dispcom- eng-2002-12-rep.pdf [Accessed 20th November 2014]
2. National Institute for Health and Care Excellence. Hypertension: clinical management of primary hypertension in adults. Available from: www.nice.org.uk/ guidance/cg127 [Accessed 20th November 2014]
3. Duminy PC, Burger PD. Fetal abnormality associated with the use of captopril during pregnancy. S Afr Med J 1981;60(21):805
4. Guignard JP, Burgener F, Calame A, et al. Persistent anuria in a neonate: a side effect of captopril? Int J Pediatr Nephrol 1981;2:133
5. Polifka JE. Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence. Birth defects Res A Clin Mol Teratol 2012;94(8): 576-98
6. Health and Social Care Information Centre. Health survey for England - 2012, Trend tables. Available from: www.hscic.gov.uk/ catalogue/PUB13219 [Accessed 20th November 2014]
7. Bateman BT, Shaw KM, Kuklina EV, et al. Hypertension in women of reproductive age in the United States: NHANES 1999-2008. PloS One 2012;7(4):e36171
8. Martin U, Foreman MA, Travis JC, et al. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008;33(5):507-11
9. Office for National Statistics. Births in England and Wales, 2013. Available from: www.ons.gov.uk/ons/rel/vsob1/birthsummary- tables-england-and-wales/2013/ stb-births-in-england-and-wales-2013.html [Accessed 20th November 2014]
10. Hall DR. Treatment of hypertension during pregnancy. S Afr Heart J 2014;11:68-74
11. Abalos E, Cuesta C, Grosso AL, et al. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013;170(1):1-7
12. Bramham K, Parnell B, Nelson-Piercy C, et al. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ 2014;348:g2301
13. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane database Syst Rev 2014;2: CD002252
14. National Institute for Health and Care Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. Available from: www. nice.org.uk/guidance/cg107 [Accessed 20th November 2014]
15. Clausen TD, Bergholt T. Chronic hypertension during pregnancy. BMJ 2014;348:g2655
16. Abstracts of the Perinatal Medicine 2014 Congress, 9-11 June 2014, Harrogate, UK. Arch Dis Child Fetal Neonatal Ed 2014;99(Suppl 1):A1-151
17. The CHIPS Trial (Control of hypertension in pregnancy study). Available from: http:// clinicaltrials.gov/show/NCT01192412 [Accessed 20th November 2014]
18. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281-357
19. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-52
20. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5): 507-20
21. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. New Eng J Med 2006; 354(23):2443-51
22. Lip GY, Churchill D, Beevers M, et al. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 1997;350(9089): 1446-7
23. Steffensen FH, Nielsen GL, Sorensen HT, et al. Pregnancy outcome with ACE-inhibitor use in early pregnancy. Lancet 1998;351(9102):596
24. Cournot MP, Vial T, Carlier P, et al. Angiotensin-converting enzyme (ACE) inhibitors during first trimester of pregnancy: a French prospective collaborative study. Drug Saf 2006;29(10): 911-1010
25. Malm H, Artama M, Gissler M, et al. First trimester use of ACE-inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008;26(1):67
26. Lennestal R, Otterblad Olausson P, Kallen B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009;65(6):615-25
27. Kallen BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17(3):255-61
28. Caton AR, Bell EM, Druschel CM, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009;54(1): 63-70
29. From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy- United States, Canada, and Israel, 1987-1995. JAMA 1997;277(15):1193-4
30. Diav-Citrin O, Shechtman S, Halberstadt Y, et al. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 2011;31(4):540-5
31. Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int 2012;2012:658310
32. Karthikeyan VJ, Ferner RE, Baghdadi S, et al. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens 2011;29(2):396-9
33. Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011;343:d5931
34. Porta M, Hainer JW, Jansson SO, et al. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. Diabetologia 2011;54(6):1298-303
35. Velazquez-Armenta EY, Han JY, Choi JS, et al. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy 2007;26(1):51-66
36. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60(2):444-50
37. Walfisch A, Al-maawali A, Moretti ME, et al. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 2011;31(6): 465-72
38. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36(4):526-36
39. Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994;45(2):403-10
40. Remuzzi A, Perticucci E, Ruggenenti P, et al. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991;39(6):1267-73
41. Remuzzi A, Puntorieri S, Battaglia C, et al. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990;85(2):541-9
42. Sarafidis PA, Li S, Chen SC, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008;121(4):332-40
43. Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol 2014;3(3):99-104
44. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13):1296-305
45. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334(1):13-18
46. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 1996;11(3):461-7
47. Jarraya F, Lakhdar R, Kammoun K, et al. Microalbuminuria: a useful marker of cardiovascular disease. Iran J Kidney Dis 2013;7(3):178-86
48. Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis 2013;7:13-24
49. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993;329(20): 1456-62
50. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118(8):577-81
51. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334(15): 939-45
52. Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352(9136): 1252-6
53. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349(9069): 1857-63
54. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135(2):73-87
55. Molnar MZ, Kalantar-Zadeh K, Lott EH, et al. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Amer Coll Cardiol 2014; 63(7):650-8
56. Williams D, Davison J. Chronic kidney disease in pregnancy. BMJ 2008;336(7637): 211-15
57. Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med 1996;335(4):226-32
58. Vellanki K. Pregnancy in chronic kidney disease. Adv Chronic Kidney Dis 2013; 20(3):223-8
59. Nevis IF, Reitsma A, Dominic A, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Amer Soc Nephrol 2011;6(11):2587-98
60. Mustafa R, Ahmed S, Gupta A, Venuto RC. A comprehensive review of hypertension in pregnancy. J Pregnancy 2012;2012:105918
61. Bramham K, Nelson-Piercy C, Brown MJ, Chappell LC. Postpartum management of hypertension. BMJ 2013;346:f894
62. Redman CW, Kelly JG, Cooper WD. The excretion of enalapril and enalaprilat in human breast milk. Eur J Clin Pharmacol 1990;38(1):99
63. Medicines and Healthcare Products Regulatory Agency. ACE inhibitors and angiotensin II receptor antagonists: recommendations on use during breastfeeding. Available from: www.mhra. gov.uk/Safetyinformation/ DrugSafetyUpdate/CON088003#ref2 [Accessed 20th November 2014]